Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- 80 and over (1)
- Administration (1)
- Administration, Oral (1)
- Adult (1)
- Aged (1)
-
- Aged, 80 and over (1)
- Amiodarone (1)
- Analgesics (1)
- Analgesics, Opioid (1)
- Antiemetics (1)
- Area Under Curve (1)
- Area under curve (1)
- Atrial Fibrillation (1)
- Atrial fibrillation (1)
- Bayes Theorem (1)
- Bayes theorem (1)
- Dose-Response Relationship, Drug (1)
- Dose-response relationship (1)
- Double-Blind Method (1)
- Double-blind method (1)
- Drug (1)
- Drug Interactions (1)
- Drug interactions (1)
- Factor Xa Inhibitors (1)
Articles 1 - 2 of 2
Full-Text Articles in Heterocyclic Compounds
Real-World Impact Of Amiodarone On Apixaban Population Pharmacokinetics In Hospitalized Patients, Samantha Kolowrat, Chazmyn Riley, Kevin Lam, Lynda Thomson, Douglas F. Stickle, Walter K. Kraft
Real-World Impact Of Amiodarone On Apixaban Population Pharmacokinetics In Hospitalized Patients, Samantha Kolowrat, Chazmyn Riley, Kevin Lam, Lynda Thomson, Douglas F. Stickle, Walter K. Kraft
Department of Pharmacology, Physiology, and Cancer Biology Faculty Papers
Despite common coadministration in nonvalvular atrial fibrillation (NVAF), there is minimal evidence regarding the impact of concomitant amiodarone use on apixaban pharmacokinetics (PK). We described the population PK of apixaban (2.5 and 5mg twice daily) in 106 hospitalized patients with and without concomitant amiodarone administration at steady state. Apixaban PK was reasonably described by a one-compartment model with first-order absorption and linear elimination. Aside from the receipt of amiodarone, age was retained as a statistically significant covariate on apparent clearance. Model-based simulations depicted concomitant amiodarone use increasing AUCT for both 2.5mg (1.58, 90% CI [1.28, 1.87]) and 5mg (1.12, 90% …
Bayesian Population Pharmacokinetic Modeling Of Ondansetron For Neonatal Opioid Withdrawal Syndrome, Kevin Lam, John Mondick, Gary Peltz, Manhong Wu, Walter Kraft
Bayesian Population Pharmacokinetic Modeling Of Ondansetron For Neonatal Opioid Withdrawal Syndrome, Kevin Lam, John Mondick, Gary Peltz, Manhong Wu, Walter Kraft
Department of Pharmacology, Physiology, and Cancer Biology Faculty Papers
Ondansetron is an anti-emetic 5-HT3 receptor antagonist being investigated for treating neonatal opioid withdrawal syndrome (NOWS). Sparse PK data were analyzed from a multicenter, double-blind clinical trial with 98 mother/neonate dyads. Pregnant women with opioid use disorder were randomized to receive either placebo or ondansetron 8 mg intravenously within 4 h of delivery. Neonates born to mothers who were randomized to ondansetron received 0.07 mg/kg orally once every 24 h for up to five doses. Using current PK data, model parameters from a two-compartmental structural model from the literature (i.e., a priori model) were updated with the Metropolis-Hastings Markov-chain Monte …